|
1
|
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
|
J Clin Oncol
|
2008
|
15.17
|
|
2
|
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
|
N Engl J Med
|
2013
|
11.93
|
|
3
|
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
|
N Engl J Med
|
2008
|
11.86
|
|
4
|
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
|
J Clin Oncol
|
2010
|
10.17
|
|
5
|
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
|
J Clin Oncol
|
2009
|
9.24
|
|
6
|
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
|
J Clin Oncol
|
2008
|
5.78
|
|
7
|
OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study.
|
J Clin Oncol
|
2006
|
5.56
|
|
8
|
Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.
|
J Clin Oncol
|
2007
|
3.33
|
|
9
|
Mutations in BRIP1 confer high risk of ovarian cancer.
|
Nat Genet
|
2011
|
3.06
|
|
10
|
Global human footprint on the linkage between biodiversity and ecosystem functioning in reef fishes.
|
PLoS Biol
|
2011
|
3.02
|
|
11
|
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
|
Lancet Oncol
|
2012
|
3.02
|
|
12
|
A germline variant in the TP53 polyadenylation signal confers cancer susceptibility.
|
Nat Genet
|
2011
|
2.43
|
|
13
|
Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer.
|
J Clin Oncol
|
2007
|
2.10
|
|
14
|
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study.
|
Oncologist
|
2012
|
1.96
|
|
15
|
Discovery of common variants associated with low TSH levels and thyroid cancer risk.
|
Nat Genet
|
2012
|
1.81
|
|
16
|
Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma.
|
Clin Transl Oncol
|
2011
|
1.46
|
|
17
|
Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
|
J Clin Oncol
|
2006
|
1.40
|
|
18
|
SEOM guidelines for endometrial cancer.
|
Clin Transl Oncol
|
2012
|
1.38
|
|
19
|
Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.
|
J Clin Oncol
|
2013
|
1.32
|
|
20
|
Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.
|
J Clin Oncol
|
2010
|
1.23
|
|
21
|
Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.
|
BMC Cancer
|
2013
|
1.09
|
|
22
|
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.
|
Clin Cancer Res
|
2013
|
1.03
|
|
23
|
Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors study.
|
Oncologist
|
2012
|
1.03
|
|
24
|
Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer.
|
Clin Transl Oncol
|
2011
|
1.02
|
|
25
|
Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study.
|
PLoS One
|
2012
|
0.96
|
|
26
|
An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer.
|
Oncologist
|
2014
|
0.96
|
|
27
|
A Phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer.
|
Int J Radiat Oncol Biol Phys
|
2006
|
0.96
|
|
28
|
First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD Group Study.
|
Oncologist
|
2012
|
0.94
|
|
29
|
Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study.
|
Crit Rev Oncol Hematol
|
2008
|
0.90
|
|
30
|
Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
|
Clin Colorectal Cancer
|
2013
|
0.90
|
|
31
|
SEOM guidelines for gastrointestinal stromal sarcomas (GIST).
|
Clin Transl Oncol
|
2012
|
0.89
|
|
32
|
Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma.
|
Mar Drugs
|
2009
|
0.85
|
|
33
|
Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status.
|
Drugs
|
2015
|
0.83
|
|
34
|
Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS).
|
J Gastrointest Cancer
|
2015
|
0.81
|
|
35
|
SEOM guidelines for cervical cancer.
|
Clin Transl Oncol
|
2012
|
0.81
|
|
36
|
Effect of uric acid on hypertension progression in spontaneously hypertensive rats.
|
Life Sci
|
2010
|
0.80
|
|
37
|
Cost-utility analysis of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in combination with gemcitabine in metastatic pancreatic cancer in Spain: results of the PANCOSTABRAX study.
|
Expert Rev Pharmacoecon Outcomes Res
|
2015
|
0.79
|
|
38
|
Phase II study of bevacizumab, capecitabine, and oxaliplatin followed by bevacizumab plus erlotinib as first-line therapy in metastatic colorectal cancer.
|
Oncol Res
|
2013
|
0.79
|
|
39
|
The (In)Significance of Race and Discrimination among Latino Youth: The Case of Depressive Symptoms.
|
Sociol Focus
|
2012
|
0.78
|
|
40
|
Ataques de Nervios and their psychiatric correlates in Puerto Rican children from two different contexts.
|
J Nerv Ment Dis
|
2009
|
0.78
|
|
41
|
MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer.
|
BMC Cancer
|
2014
|
0.77
|
|
42
|
Diabetes mellitus following cisplatin treatment.
|
Acta Oncol
|
2003
|
0.77
|
|
43
|
Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study.
|
Acta Oncol
|
2008
|
0.75
|
|
44
|
Effect of preslaughter events on the prevalence of Salmonella in market-weight turkeys.
|
J Food Prot
|
2006
|
0.75
|
|
45
|
The safety of electroconvulsive therapy in patients with prolonged QTc intervals on the electrocardiogram.
|
J ECT
|
2011
|
0.75
|
|
46
|
Low prevalence of Listeria monocytogenes in cull sows and pork.
|
J Food Prot
|
2008
|
0.75
|
|
47
|
Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II-III rectal cancer.
|
Clin Transl Oncol
|
2012
|
0.75
|
|
48
|
Irinotecan (CPT-11) combined with bolus 5-fluorouracil/leucovorin (Saltz regimen) as first-line chemotherapy of patients with advanced colorectal cancer.
|
Anticancer Drugs
|
2006
|
0.75
|
|
49
|
Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.
|
Oncologist
|
2017
|
0.75
|